Cellectar to Participate at the Oppenheimer Rare & Orphan Disease Summit on May 21, 2021

Rhea-AI Summary

On May 14, 2021, Cellectar Biosciences (NASDAQ: CLRB) announced its participation in the Oppenheimer Rare & Orphan Disease Summit on May 21, 2021. The company will be available for one-on-one meetings and will host an on-demand presentation for registered participants. Cellectar is focused on developing cancer-targeted therapies using its proprietary Phospholipid Drug Conjugate™ delivery platform. The company’s product pipeline includes CLR 131 and other preclinical PDC programs aimed at enhancing treatment efficacy and safety for cancer patients.

FLORHAM PARK, N.J., May 14, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the company will participate and be available for 1x1 meetings at the following upcoming conference:

Oppenheimer Rare & Orphan Disease Summit
Date:	May 21, 2021
Time:	On demand presentation for registered participants
	Available for 1x1 meetings
Webcast:	To register, click on the link HERE

A replay of the presentation will be available on the Events page of the company website.

About Cellectar Biosciences, Inc.
Cellectar Biosciences is focused on the discovery and development of drugs for the treatment of cancer. The company is developing proprietary drugs independently and through research and development collaborations. The company’s core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop PDCs that specifically target cancer cells, delivering improved efficacy and better safety as a result of fewer off-target effects. The company’s PDC platform possesses the potential for the discovery and development of the next-generation of cancer-targeting treatments, and it plans to develop PDCs independently and through research and development collaborations.

The company’s product pipeline includes CLR 131, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope) and proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets.

For more information, please visit www.cellectar.com or join the conversation by liking and following us on the company’s social media channels: Twitter, LinkedIn, and Facebook.

Contacts

Investors:
Monique Kosse
Managing Director
LifeSci Advisors
212-915-3820
monique@lifesciadvisors.com

FAQ

What conference is Cellectar Biosciences participating in May 2021?

Cellectar Biosciences is participating in the Oppenheimer Rare & Orphan Disease Summit on May 21, 2021.

What is the focus of Cellectar Biosciences?

Cellectar Biosciences focuses on the discovery and development of cancer-targeted therapies.

What is CLR 131?

CLR 131 is a small-molecule Phospholipid Drug Conjugate developed by Cellectar for targeted delivery of radioactive iodine-131.

Will there be a replay of Cellectar's presentation?

Yes, a replay of Cellectar's presentation will be available on the company's Events page.

How can I register for the Oppenheimer Rare & Orphan Disease Summit?

You can register for the conference by visiting the Oppenheimer event page [here](https://www.oppenheimer.com/events/2021/rare-orphan-disease-summit.aspx).